Close Menu

TGen

The WHO and FIND are supporting NGS-based testing in low-resource settings, while a resistance testing program at New York State's Wadsworth Center has matured.

Launched by both national labs and regional and specialty firms, the offerings provide testing as well as guidance on how to best structure testing programs.

The partners will work together on a US commercialization strategy for Genetic Technologies' line of existing and future polygenic risk tests.

The partners inked a licensing deal to market and distribute TGen's DeepChek-TB as a compact, portable, and affordable diagnostic model for physician use.

Crowdfunding will help move the targeted sequencing-based test through the development process in hopes of commercializing it.